PURPOSE To evaluate the 24-month effectiveness of polypoidal lesion-selective photodynamic therapy (PDT) combined with antivascular endothelial growth factor (VEGF) therapy for polypoidal choroidal vasculopathy (PCV) with branching vascular networks (BVNs) involving the fovea with 1 or more polyps. STUDY DESIGN A retrospective case series. PATIENTS AND METHODS Twenty-six eyes from 25 PCV patients treated with polypoidal lesion-selective PDT combined with aflibercept were included in the study. The main outcome measure was change in best-corrected visual acuity (BCVA), and the secondary outcome measures were changes in central retinal thickness and subfoveal choroidal thickness on optical coherence tomography (OCT), status of exudation at 24 months, and number of additional treatments. RESULTS Fourteen eyes of 14 patients showed treatment-naïve PCV, and 12 eyes of 11 patients were switched from anti-VEGF monotherapy. The baseline mean logMAR BCVA was 0.43, and this had increased significantly, by 0.31, at 24 months (P = .034). The mean central retinal thickness (CRT) and central choroidal thickness (CCT) were significantly lower at all time points than those at baseline. The mean number of additional injections of aflibercept was 3.1 (range, 0-9), and that of additional PDT treatments was 0.5 (range, 0-2). CONCLUSION Polypoidal lesion-selective PDT with aflibercept was effective for relatively large, fovea-involved PCV, with significant visual improvement at 24 months.

中文翻译：

---

玻璃体腔内抗血管内皮生长因子对息肉样病变的选择性光动力疗法对息肉样脉络膜血管病的疗效。

目的评估息肉病灶选择性光动力疗法（PDT）联合抗血管内皮生长因子（VEGF）疗法治疗多发性脉络膜血管病（PCV）伴有分支性中央凹并伴有1个或多个息肉的分支性血管网（BVN）的24个月疗效。研究设计回顾性案例系列。患者与方法本研究纳入了25例接受息肉样病变选择性PDT联合阿柏西普治疗的PCV患者的26只眼。主要结局指标是最佳矫正视力（BCVA）的变化，次要结局指标是光学相干断层扫描（OCT）的中央视网膜厚度和中央凹脉络膜下厚度的变化，24个月时的渗出状况以及增加的数量治疗。结果14例患者的14眼显示未接受过PCV，11例患者的12眼转用抗VEGF单药治疗。基线平均logMAR BCVA为0.43，在24个月时显着增加0.31（P = .034）。在所有时间点，平均中央视网膜厚度（CRT）和中央脉络膜厚度（CCT）均明显低于基线时间。额外注射aflibercept的平均次数为3.1（范围为0-9），而其他PDT治疗的平均次数为0.5（范围为0-2）。结论含阿柏西普的息肉样病变选择性PDT对于相对大的黄斑中心凹相关的PCV有效，在24个月时有明显的视觉改善。在24个月时（P = .034）。在所有时间点，平均中央视网膜厚度（CRT）和中央脉络膜厚度（CCT）均明显低于基线时间。额外注射aflibercept的平均次数为3.1（范围为0-9），而其他PDT治疗的平均次数为0.5（范围为0-2）。结论含阿柏西普的息肉样病变选择性PDT对于相对大的黄斑中心凹相关的PCV有效，在24个月时有明显的视觉改善。在24个月时（P = .034）。在所有时间点，平均中央视网膜厚度（CRT）和中央脉络膜厚度（CCT）均明显低于基线时间。额外注射aflibercept的平均次数为3.1（范围为0-9），而其他PDT治疗的平均次数为0.5（范围为0-2）。结论含阿柏西普的息肉样病变选择性PDT对于相对大的黄斑中心凹相关的PCV有效，在24个月时有明显的视觉改善。